NCT05884619 is a NA clinical trial of Dual-target deep brain stimulation in Alcohol Use Disorder, sponsored by Second Xiangya Hospital of Central South University.

Who is sponsoring NCT05884619?

NCT05884619 is sponsored by Second Xiangya Hospital of Central South University.

What drugs are being tested in NCT05884619?

Interventions in NCT05884619: Dual-target deep brain stimulation.

What condition does NCT05884619 study?

NCT05884619 studies Alcohol Use Disorder, Deep Brain Stimulation.

Is NCT05884619 still recruiting?

NCT05884619 is currently status unknown. Last updated 13 September 2023.

Last reviewed 2023-09-13 · How we verify

NCT05884619

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

Efficacy and Safety of Dual-target Deep Brain Stimulation for Treatment-resistant Alcohol Use Disorder

Status unknown NA Last updated 13 September 2023

What this trial tests

NA trial testing Dual-target deep brain stimulation in Alcohol Use Disorder in 12 participants. Status unknown.

Timeline

14 August 2023

Primary endpoint
30 December 2024

30 December 2024

Quick facts

Lead sponsor	Second Xiangya Hospital of Central South University
Phase	NA
Status	Status unknown
Study type	INTERVENTIONAL
Allocation	na
Design	single group
Masking	none
Primary purpose	treatment
Enrollment	12
Start date	14 August 2023
Primary completion	30 December 2024
Estimated completion	30 December 2024
Sites	4 locations across China

Drugs / interventions tested

Dual-target deep brain stimulation

Conditions studied

Alcohol Use Disorder — all drugs for Alcohol Use Disorder →
Deep Brain Stimulation — all drugs for Deep Brain Stimulation →

Sponsor

Second Xiangya Hospital of Central South University

Who can join

Adults 18 to 65, any sex, with Alcohol Use Disorder or Deep Brain Stimulation. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

This is a multi-center, single arm, prospective, open-label, extendable study for the efficacy and safety of dual-target deep brain stimulation for treatment-resistant alcohol use disorder.

Publications & conference data

2 peer-reviewed publications reference this trial (live from Europe PMC):

Deep Brain Stimulation for the Management of Refractory Neurological Disorders: A Comprehensive Review.
Rissardo JP, Vora NM, Tariq I, Mujtaba A, et al · · 2023 · cited 17× · PMID 38004040 · DOI 10.3390/medicina59111991
Best practices for clinical trials of deep brain stimulation for neuropsychiatric indications.
Tremblay-McGaw AG, Hamlat EJ, Becker NC, Astudillo Maya DA, et al · · 2025 · cited 1× · PMID 40309667 · DOI 10.3389/fnhum.2025.1572972

Verify or expand the search:

Other recruiting trials for Alcohol Use Disorder

Currently open trials in the same condition.

NCT06860607 — Environment and Alcohol: A Pilot Study · Phase 1 · recruiting
NCT07325266 — Human Laboratory Study of Apremilast for Alcohol Use Disorder · Phase 2 · recruiting
NCT07046819 — Tirzepatide in MetALD · Phase 2 · recruiting
NCT07279558 — Cannabidiol and Alcohol Use Disorder Phenotypes · Phase 2 · recruiting
NCT07056894 — Effects of Action-Based Cognitive Remediation on Substance Misuse in Early Phase Psychosis · NA · recruiting

Other Second Xiangya Hospital of Central South University trials

Trials by the same sponsor.

NCT07278947 — ACT-based Parenting Program for Caregivers of Children With Hearing Loss Post-cochlear: A Pilot Randomised Controlled Tr · NA · not yet recruiting
NCT07460336 — Effects of Cofrogliptin on Beta-Cell Function in LADA Patients · NA · not yet recruiting
NCT06951646 — ctDNA-MRD Guided Escalation of Ivonescimab and Docetaxel in Advanced NSCLC With Long-Term Responses to First-line Immuno · Phase 2 · recruiting
NCT07343154 — Multimodal Brain Function in Migraine Patients With Patent Foramen Ovale · not yet recruiting
NCT07338487 — A Clinical Study of Nanocrystalline Megestrol Acetate in Concurrent Chemoradiotherapy for Locally Advanced Cervical Canc · Phase 1 · recruiting

Verify against primary sources

ClinicalTrials.gov — authoritative US registry record
WHO ICTRP — international registry index
EU Clinical Trials Register
Sponsor press releases (Google)

Data sources for this page

Trial protocol + status: ClinicalTrials.gov NCT05884619 (US National Library of Medicine, public domain)
Publications: Europe PMC API search by NCT ID, retrieved 10 June 2026
Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
Sponsor: as reported to ClinicalTrials.gov by Second Xiangya Hospital of Central South University
Last refreshed: 13 September 2023

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT05884619.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing